BR-02001

N/A

Report date: 2024/12/04 15:18:00

Base Information

Drug NameBR-02001

Drug Alias NamehCTLA4Ig

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCluster of differentiation 86 modulatorsT-cell-specific surface glycoprotein CD28 inhibitorsCytotoxic T-Lymphocyte-Associated Antigen 4 stimulants

TargetsCluster of differentiation 86T-cell-specific surface glycoprotein CD28Cytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBoryung Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBoryung Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A